Shire to sell its oncology business to Servier for $2.4 billion

17 Apr 2018

Sale of oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing the company's leadership in rare diseases.

Shire has entered into a definitive agreement with Servier to sell its oncology business for $2.4 billion. Shire’s oncology business includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-US rights to Onivyde (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early-stage immuno-oncology pipeline collaborations.

Shire to sell its oncology business to Servier for $2.4 billion

Flemming Ornskov, Shire CEO, commented: “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the Oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy. We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.

“We are confident that Servier will continue to invest in this business and our colleagues who are expected to transfer as part of the transaction in order to meet the needs of cancer patients globally.

“The proceeds from the transaction increase optionality and Shire’s Board will consider returning the proceeds of the sale to shareholders through a shareholder-approved share buyback after the current offer period regarding Takeda’s possible offer for Shire concludes.”

Olivier Laureau, Servier Group President, commented: “The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present. Our goal is to bring these treatments to greater numbers of cancer patients around the world. We thoroughly look forward to welcoming Shire’s oncology teams who will join Servier after the closing."

Read More

Related tags

Market News

Related news

BIA Separations expands with new upstream processing facility

BIA Separations expands with new upstream processing facility

20 Sep 2018

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Recipharm connects to European Hub for serialisation compliance

Recipharm connects to European Hub for serialisation compliance

18 Sep 2018

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

Read more 
Bosch to unveil new laboratory device for continuous manufacturing

Bosch to unveil new laboratory device for continuous manufacturing

18 Sep 2018

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Read more 
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

17 Sep 2018

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Read more 
Cambrex expands manufacturing footprint with acquisition

Cambrex expands manufacturing footprint with acquisition

16 Sep 2018

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Read more 
NMPA approves fruquintinib capsules for metastatic colorectal cancer

NMPA approves fruquintinib capsules for metastatic colorectal cancer

13 Sep 2018

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

Read more 
Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more